Clinical Trial Search

Primary: Percentage of Participants With Progression or Death in Intent-to-Treat (ITT) Population — 69.4; 63.6 percentage of participants

Primary: Primary--Percent Change of Pre- to Post-Operative Hemoglobin — 20.1; 22.5 Percent Change — p=0.2

Primary: Inspiratory Capacity (IC) Peak Value — 2.87; 2.94; 2.99; 2.85 Liters

Primary: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) on Day 85 — 0.154; 0.095 Liter — p=<0.001

Primary: Percentage of Days With Subcutaneous Octreotide as Rescue Medication — 33.72; 48.49 Percentage of days — p=0.0165

Primary: Number of Participants Who Died and With Adverse Events (AEs) Leading to Discontinuation, Hyperbilirubinemia, Jaundice, First-degree Arterioventricular Block…

Primary: Overall Survival — 21.5; 24.1 Months — p=0.883

Primary: Proportion of Participants With Majority Reader Self-agreement in Ischemia Assessment Between First and Second Stress Scans — 0.92; 0.95 proportion of participants

Primary: Recurrence of an Infarct, Defined as a Stroke or a New or Enlarged Silent Cerebral Infarct — 2.0; 4.8 infarct recurrence per 100 person years

Primary: Responder Patients — 72.2 percentage of subjects

Primary: Duration of Postoperative Analgesia — 334; 280 time in minutes

Primary: Evaluate the Number of Clinical Events (Pooled) Occurring Between 3-15 Months Following a Switch/Stabilization of the Antipsychotic Agents Among Patients Who Receive…

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 71.9; 85.4; 92.9 percentage of participants

Primary: Mean Self-report Weekly Craving Via Obsessive Compulsive Drinking Scale (OCDS) — 21.273; 20.700; 18.500; 21.458 units on a scale

Primary: Baseline Adjusted Percent Predicted Forced Expiratory Volume In 1 Second (FEV1) Area Under The Concentration Time Curve Up From Time Zero up to 6 Hours (AUC0-6) Over 3…